Endocrine effects of the tyrosine kinase inhibitor vandetanib in patients treated for thyroid cancer. [electronic resource]
Producer: 20111123Description: 2741-9 p. digitalISSN:- 1945-7197
- Adenocarcinoma, Follicular -- blood
- Adenocarcinoma, Papillary -- blood
- Adult
- Aged
- Aged, 80 and over
- Blood Glucose
- Calcium -- blood
- Cross-Over Studies
- Enzyme Inhibitors -- therapeutic use
- ErbB Receptors -- antagonists & inhibitors
- Female
- Humans
- Male
- Middle Aged
- Parathyroid Hormone -- blood
- Piperidines -- therapeutic use
- Proto-Oncogene Proteins c-ret -- antagonists & inhibitors
- Quinazolines -- therapeutic use
- Receptors, Vascular Endothelial Growth Factor -- antagonists & inhibitors
- Testosterone -- blood
- Thyroid Neoplasms -- drug therapy
- Treatment Outcome
- Vitamin D -- blood
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.